Tech Company Financing Transactions
Kate Therapeutics Funding Round
Kate Therapeutics, based in San Diego, secured $51 million in funding from Versant Ventures, Westlake Village BioPartners and Osage University Partners.
Transaction Overview
Company Name
Announced On
6/8/2023
Transaction Type
Venture Equity
Amount
$51,000,000
Round
Series A
Investors
Versant Ventures (Lead Investor)
Westlake Village BioPartners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the advancement of its initial internal portfolio of muscle and heart disease programs, including myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), which are two of the leading causes of adult-onset muscular dystrophy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10675 Sorrento Valley Rd 150
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases. We are based in San Diego, California. Kate Therapeutics is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapy and enable the pursuit of a broader set of disease targets that are otherwise difficult to drug with current technologies. Data supporting one of our approaches to improve AAV-mediated gene delivery has been published (Tabebordbar et al., Cell, 2021). Our novel capsids provide superior muscle and heart transduction and liver de-targeting compared to the naturally occurring serotypes currently used in clinical trials. This may enable more complete tissue transduction at significantly lower and safer doses, addressing a major limita
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Forrest
Chief Medical Officer
Christopher Kurt
Chief Scientific Officer
Sharif Tabebordbar
Browse more venture capital transactions:
Prev: 6/8/2023: HyperPlay venture capital transaction
Next: 6/8/2023: eFFECTOR Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs